Sprint Bioscience AB has announced positive results from a preclinical proof-of-concept (POC) study performed within the company’s VRK1 program that showed that VRK1 inhibition selectively kills glioblastoma cells with low VRK2 levels, while cells with normal VRK2 levels are not affected.